Maintenance Therapy, Survivorship, and Monitoring

Completing the initial rounds of chemotherapy and surgery is a monumental milestone. For many patients, the transition into the “maintenance and survivorship” phase is a mix of relief and new anxieties. Modern ovarian cancer care has moved toward an active strategy designed to keep the cancer from returning for as long as possible.

The Power of Maintenance Therapy

Maintenance therapy is treatment given after your initial chemotherapy to help prevent or delay a recurrence. Your molecular profile (BRCA and HRD status) dictates your eligibility for these treatments ^[1].

PARP Inhibitors

Drugs like olaparib, niraparib, and rucaparib have fundamentally changed the outlook for patients with advanced ovarian cancer ^[2][3]. They work by trapping the cancer cells’ ability to repair their DNA.

• They are highly effective for patients with BRCA mutations or HRD-positive tumors ^[4].
• Some PARP inhibitors are also approved for patients regardless of BRCA status, though the degree of benefit varies ^[5][6].

The Reality of Side Effects: While effective, PARP inhibitors are serious medications. Common side effects include severe fatigue, persistent nausea, and anemia (low red blood cells). Crucially, there is a rare but severe risk of developing secondary blood cancers, such as Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) ^[6]. Because of this, your medical team will monitor your blood counts very closely.

Angiogenesis Inhibitors

Bevacizumab is an “angiogenesis inhibitor,” meaning it prevents the tumor from growing the new blood vessels it needs to survive. It is often used in combination with PARP inhibitors (like olaparib) for HRD-positive patients to maximize the time without disease progression ^[7].

Monitoring and the “Surveillance Paradox”

The standard way to monitor for recurrence involves regular physical exams, symptom checks, and CA-125 blood tests ^[8].

However, there is a known “surveillance paradox” in ovarian cancer. Older clinical trials showed that immediately starting traditional chemotherapy the moment a CA-125 level rises (in a patient who feels completely fine) did not actually extend life compared to waiting until physical symptoms appeared.

Why does this paradox exist? Because starting traditional chemotherapy early simply subjected the patient to continuous toxicity, destroying their quality of life sooner without changing the ultimate outcome. The goal was to maximize the time the patient felt well.

Hope on the Horizon: Today, with the advent of PARP inhibitors and other targeted therapies, the way doctors act on a rising CA-125 is evolving. A rising number doesn’t mean immediate despair or an automatic return to harsh chemotherapy; it’s a signal for you and your doctor to strategize.

Navigating Life After Treatment

Survivorship is about reclaiming your life.

• Scanxiety and Fear of Recurrence: Fear of the cancer returning is a completely normal, nearly universal experience ^[8]. Patient-Initiated Follow-Up (PIFU), where you report symptoms rather than sticking to a rigid, anxiety-inducing scan schedule, has been shown to be a feasible way to manage survivorship without increasing fear ^[8].
• Physical Well-being: Many survivors deal with long-term side effects like chronic fatigue or neuropathy. Do not dismiss these. Ask for referrals to physical therapy and specialized survivorship clinics.

Your journey doesn’t end when chemotherapy does. Building a survivorship plan with your care team ensures that you are actively managing both your physical health and your emotional well-being.